10
Aug
2023
Sage Gets FDA OK for PPD, Wegovy’s Home Run, & Illumina’s Gloomy Quarter
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Aug
2023
Challenges of Adopting Data Science & AI in Pharma/Biotech
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Aug
2023
Digging into Data, Finding New Drug Targets: Colin Hill on The Long Run
Today’s guest on The Long Run is Colin Hill. He’s the co-founder and CEO of Aitia (pronounced Ay-tee-ah). The company was founded in 2000, and previously known as GNS Healthcare. The GNS part was short for Gene Network Sciences, which gives you some sense of what it was about. Aitia is a new name to reflect a new strategy. The... Read More
8
Aug
2023
Recursion Screens Protein-Small Molecule Interactions at Vast Scale
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2023
Revolution Absorbs EQRX, Pfizer Itches to Close Seagen, & Boundless Preps for IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Aug
2023
Kyverna Tacks on $60M to Take CAR-T for Autoimmunity Further in the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Jul
2023
Lessons For Biopharma from a Healthcare AI Pioneer
As drug developers consider how to leverage AI and other emerging digital and data technologies, they look to related businesses, such as healthcare systems, for lessons and learning. We would be hard-pressed to find a better guide to AI in healthcare than Ziad Obermeyer, an emergency room physician and health science researcher at the University of California-Berkeley. His research... Read More
27
Jul
2023
Alnylam’s Big Roche Deal, Biogen Cuts 1,000 Jobs, & Pneumococcal Vaccine Competition
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jul
2023
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jul
2023
A-Alpha Bio Raises $22.4M to Further Build SynBio and AI Drug Discovery Platform
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2023
Betting on Bold and Brave Ideas for Cancer: Yung Lie on The Long Run
Today’s guest on The Long Run is Yung Lie. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation. The New York-based foundation supports some of the best young scientists around the US and gives them funds to pursue their bold and brave ideas. To give just one example, it bet on cancer immunotherapy research when it... Read More
20
Jul
2023
FTC Scrutinizes M&A, Tessier-Lavigne Steps Down, and BridgeBio’s Comeback
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jul
2023
Neumora Advances to Phase III with Depression Drug, Hires AbbVie Vet as CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jul
2023
Westlake Village Raises $450M for Biotech Startups in LA and Beyond
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jul
2023
Recursion’s Big Day, FDA OKs OTC Birth Control & a Midsummer IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jul
2023
Timmerman Traverse for Life Science Cares Hits $1M Goal to Fight Poverty
I’m delighted to share some good news. The Timmerman Traverse for Life Science Cares has hit its goal in 2023. Together, we have raised more than $1 million to fight poverty in five biotech hubs around the US. The funds will help fulfill basic human needs like food and shelter. They will also go toward education and job training to... Read More
11
Jul
2023
Septerna, Backed by Third Rock and RA, Gets $150M for GPCR Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2023
Detecting Cancer Early When It’s Most Treatable: Kevin Conroy on The Long Run
Today’s guest on The Long Run is Kevin Conroy. Kevin is the chairman and CEO of Madison, Wis.-based Exact Sciences. Exact Sciences has grown over the past decade into a success story for cancer screening and diagnosis. It’s best known for marketing the noninvasive Cologuard test that screens people for colorectal cancer. It also markets the Oncotype DX test that’s... Read More
10
Jul
2023
Lessons Learned from the Intense Back-and-Forth Over a $1B Acquisition
Since 2018, about 90 biotech companies have been acquired for more than $500 million. That’s only about 15 to 20 companies per year, a tiny fraction of the approximately 10,000 biotechnology companies around the world. I was privileged to be part of one of those transactions, the sale of Albireo Pharma to Ipsen in January for $952 million upfront, plus... Read More
29
Jun
2023
Vertex Gears Up for T1D, GSK TB Vaccine Gets Boost, & Regeneron Stumbles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.